Meiogenix Announces $13 Million Series A Financing Round Led By Sofinnova Partners
12/14/21, 3:00 AM
Location
paris
Money raised
$13 million
Round Type
series a
Meiogenix, an agriculture biotech company using the process of Chromosome Editing to expand genetic diversity in food and agriculture, announced today the closing of a $13 million (€11 million) Series A financing round, led by Sofinnova Partners, with participation from Genoa Ventures, Bpifrance, Casdin Capital and Alexandria Venture Investments.
Company Info
Location
paris, ile de france, france
Additional Info
The Meiogenix platform addresses the $50 billion commercial seed market and breeding capabilities of large and essential crops like corn, wheat, rice, soybeans and tomatoes. Meiogenix's relationships with innovative industry leaders like Bayer further demonstrate the enormous potential for the Meiogenix platform to usher in the next stage of progress for the agricultural industry." Meiogenix has developed an innovative approach to common problems in agriculture, addressing key global food and industrial challenges. "Meiogenix has the potential to revolutionize the way we enhance the natural properties of plants so that they are more resistant to viruses, better tasting, and produce higher yield. Meiogenix has collaborations with Cornell and Bayer to help develop crops that improve our food supply while caring for our environment. Meiogenix is a pioneer in chromosome editing, developing broadly applicable gene and chromosome editing capabilities that restore essential biodiversity to agriculture, enabling unity between natural ecosystems and our food production.